In one paragraphArticle in Toxins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors.
Evoli N LopezLaboratorio de Bioquímica y Biología Molecular, Centro de Química del Instituto de Ciencias (ICUAP), Benemérita Universidad Autónoma de Puebla, Puebla 72570, Mexico.ORCID 0009-0001-1927-6635 Guadalupe Delgado-LópezLaboratorio de Biología Celular del Cáncer, Centro de Investigación Biomédica de Oriente, Instituto Mexicano del Seguro Social, Puebla 74360, Mexico.ORCID 0000-0002-9648-9263 Paola MaycotteLaboratorio de Bioquímica Metabólica, Centro de Investigación Biomédica de Oriente, Instituto Mexicano del Seguro Social, Puebla 74360, Mexico.ORCID 0000-0003-4059-0554 Pablo Hernández-JáureguiLaboratorio de Biología Celular del Cáncer, Centro de Investigación Biomédica de Oriente, Instituto Mexicano del Seguro Social, Puebla 74360, Mexico.ORCID 0000-0002-6562-3933 Irma Herrera-CamachoLaboratorio de Bioquímica y Biología Molecular, Centro de Química del Instituto de Ciencias (ICUAP), Benemérita Universidad Autónoma de Puebla, Puebla 72570, Mexico.ORCID 0000-0003-2426-8469 Nora Hilda Rosas-MurrietaLaboratorio de Bioquímica y Biología Molecular, Centro de Química del Instituto de Ciencias (ICUAP), Benemérita Universidad Autónoma de Puebla, Puebla 72570, Mexico.ORCID 0000-0002-4605-670X Eunice López-MuñozUnidad de Investigación Médica en Medicina Reproductiva UMAE Hospital de Gineco Obstetricia No. 4, Luis Castelazo Ayala, Instituto Mexicano del Seguro Social, Mexico City 01090, Mexico.ORCID 0000-0002-6552-170X Claudia Teresita Gutiérrez-QuirozDepartamento de Anatomía Patológica, Centro Médico Nacional "General de División Manuel Ávila Camacho", Hospital de Especialidades, Instituto Mexicano del Seguro Social, Puebla 72089, Mexico.ORCID 0000-0001-6569-4531 Uriel Ramírez-CarreraDepartamento de Anatomía Patológica, Centro Médico Nacional "General de División Manuel Ávila Camacho", Hospital de Especialidades, Instituto Mexicano del Seguro Social, Puebla 72089, Mexico.
Cindy BandalaLaboratorio de Neurociencia Traslacional en Enfermedades Crónicas y Emergentes, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City 11340, Mexico.ORCID 0000-0002-7414-2621 Lourdes Millán-Pérez-PeñaLaboratorio de Bioquímica y Biología Molecular, Centro de Química del Instituto de Ciencias (ICUAP), Benemérita Universidad Autónoma de Puebla, Puebla 72570, Mexico.ORCID 0000-0002-4139-5577 Maricruz Anaya-RuizLaboratorio de Biología Celular del Cáncer, Centro de Investigación Biomédica de Oriente, Instituto Mexicano del Seguro Social, Puebla 74360, Mexico.ORCID 0000-0002-3193-3730 Funding
Coordinación de Investigación en Salud. IMSS (R-2018-2106-036)
6 · The paper itselfAbstract
Triple-negative breast cancer (TNBC) continues to be a medical challenge requiring multiple treatment options. SV2A, a protein involved in vesicular release, has emerged as a promising biomarker for various cancers. Research shows that botulinum neurotoxin type A (BoNT/A), which binds to SV2A, the BoNT/A receptor, can inhibit the growth of prostate and breast cancer cells, suggesting its potential as an alternative treatment for breast cancer. The purpose of this study was to determine the potential of BoNT/A to inhibit tumor growth in a mouse preclinical model. BoNT/A was evaluated for its effects in an in vitro model employing 4T1 cells and in an in vivo model of orthotopically inoculated 4T1 cells in BALB/c mice. BoNT/A inhibited the proliferation of 4T1 cells, which express the SV2A protein; decreased tumor growth in the preclinical model; and decreased inflammation, associated with fewer blood neutrophils and monocytes, suggesting an immunomodulatory and anti-inflammatory effect. The effect of BoNT/A on the TNBC model supports its use as a repurposed drug for this type of aggressive cancer. Our results emphasize the significance of the SV2A receptor and its interaction with BoNT/A as promising therapeutic targets, particularly for TNBC.
Indexed as
Antineoplastic AgentsBotulinum Toxins, Type ATriple Negative Breast NeoplasmsAnimalsCell Line, TumorCell ProliferationFemaleHumansMiceMice, Inbred BALB CNerve Tissue ProteinsReceptors, VirusAntineoplastic AgentsBotulinum Toxins, Type ANerve Tissue ProteinsReceptors, Virus4T1botulinum neurotoxin Adrug repurposingimmune systempreclinical modelSV2ATNBC
Identifiers
PMID42188614
PMCPMC13211571
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390